

ASX Announcement

01 October 2026

NeuroScientific Appoints Leading Clinical Research Organisation for Phase 2 Crohn's Disease Trial

Southern Star Research appointed to support NSB's planned Phase 2 clinical trial for refractory Crohn's disease in Australia and the United States

Highlights

- **NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) has appointed Southern Star Research to conduct its planned Phase 2 clinical trial for refractory Crohn's disease in Australia and the United States.**
- **Southern Star Research is a leading Australian clinical research organisation (CRO) with an excellent track record of conducting clinical trials across multiple geographies with a focus on quality, collaboration and scientific excellence across a broad range of therapeutic areas and clinical phases.**
- **Southern Star Research will manage the clinical sites, engage with clinicians and coordinate StemSmart™ treatment logistics with trial initiation planned by the end of CY2026.**
- **The appointment of Southern Star Research represents a key operational milestone in progressing the Phase 2 clinical trial that, along with manufacturing scale-up activities¹, establishes NSB's foundation for entry into the ~US\$13 billion global Crohn's disease market².**
- **StemSmart™ is a patented stem cell technology platform targeting immune-mediated severe inflammatory diseases with a large treatment-resistant population, such as refractory Crohn's disease.**

NeuroScientific Biopharmaceuticals Limited (ASX:NSB) ("NeuroScientific", "NSB" or the "Company"), an innovative Australian biotechnology company developing novel technologies targeted at immune-mediated inflammatory diseases with large treatment-resistant populations, is pleased to announce that it has contracted Southern Star Research Pty Ltd ("Southern Star Research"), a leading Australian CRO, to initiate start-up activities for the Company's planned Phase 2 clinical trial evaluating StemSmart™ in patients with refractory Crohn's disease in Australia and the United States.

The appointment represents a key operational milestone in progressing the planned Phase 2 clinical trial for StemSmart™, with Southern Star Research to provide clinical site and study management services for the trial. The Company is targeting initiation of the planned clinical trial by the end of CY2026.

Southern Star Research is an Australian-based, full-service, independent mid-sized CRO that provides comprehensive, globally recognised CRO services while retaining an agile and client-focused partnership for small to mid-sized Biotech companies. Southern Star Research supports biotechnology, pharmaceutical and medical device companies from early through late phase clinical development.

NSB Chief Executive Officer, Mr Nathan Smith, commented:

“We are delighted to appoint Southern Star Research to deliver StemSmart™ to patients suffering from treatment-resistant Crohn’s disease. Southern Star Research’s capabilities are a strong fit for our program as we progress towards clinical site start-up and engagement with principal investigators. This appointment is a key operational milestone towards the initiation of the Phase 2 clinical trial by the end of CY2026.”

Southern Star Research will be responsible for identification, set-up and management of clinical sites on behalf of NSB in Australia and the US, engagement with clinicians and principal investigators, and logistics and delivery of NSB’s StemSmart™ product to patients enrolled in the clinical trial. NSB is engaging with separate organisations to conduct data management and safety management services for the clinical trial.

NSB’s StemSmart™ product is derived from adult human donor bone marrow-sourced mesenchymal stem cells (MSCs) and is produced using a patented manufacturing process that has been designed to improve therapeutic activity and clinical response, as well as modulate pathological immune responses that are often associated with severe and chronic inflammatory conditions. Early indications from a previous Phase 2 trial in refractory Crohn’s disease suggest StemSmart™ MSCs are potent, efficacious and safe².

¹ ASX Announcement (17 March 2026) – “StemSmart™ Manufacturing Scale-Up Transfer Advances”

² ASX Announcement (16 April 2025) – “NeuroScientific to Acquire Leading Stem Cell Technology”

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Limited.

For more information, please contact:

Nathan Smith

Chief Executive Officer

NeuroScientific Biopharmaceuticals Ltd

ir@neuroscientific.com

Jane Morgan

Investor & Media Relations

Jane Morgan Management

jm@janemorganmanagement.com.au

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company’s research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic options demonstrate limited efficacy or durability. NSB applies advanced preclinical and translational strategies to support the development of first-in-class or best-in-class biologics addressing significant unmet clinical need.



Targeting Crohn's Disease with StemSmart™ Technology

NSB is prioritising the application of its proprietary StemSmart™ technology targeting refractory Crohn's- a severe and treatment-resistant form of the condition. NSB's StemSmart™ product is derived from adult human donor bone marrow-sourced MSCs that is produced using a patented manufacturing process developed at Royal Perth Hospital, Western Australia and designed to improve therapeutic activity and clinical response.

The Company is planning Phase 2 clinical trials to further evaluate safety and preliminary efficacy in refractory and/or fistulising Crohn's disease, with the goal of making the treatment available to patients for whom current therapies remain inadequate.

Forward Looking Statements

This announcement may contain certain "forward-looking statements". Forward looking statements can generally be identified by the use of forward-looking words such as, "expect", "should", "could", "may", "predict", "plan", "will", "believe", "forecast", "estimate", "target" and other similar expressions. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

You are strongly cautioned not to place undue reliance on forward looking statements, including in respect of the financial or operating outlook for the Company. Except as required by law or any relevant listing rules of the ASX, the Company assumes no obligation to provide any additional or updated information or to update any forward-looking statements, whether as a result of new information, future events or results, or otherwise. Nothing in this announcement will, under any circumstances (including by reason of this announcement remaining available and not being superseded or replaced by any other presentation or publication with respect to the Company, or the subject matter of this announcement), create an implication that there has been no change in the affairs of the Company since the date of this announcement.